Labaran Waya

Jardiance yana taimaka wa manya biyo bayan gazawar zuciya

Written by edita

Manya da aka kwantar da su a asibiti don raunin zuciya mai tsanani sun kasance 36% mafi kusantar samun fa'idar asibiti sama da kwanaki 90 idan an fara a Jardiance® (empagliflozin) bayan daidaitawa da kuma kafin fitarwa idan aka kwatanta da placebo a cikin gwaji na III EMPULSE, Boehringer Ingelheim da Eli Lilly da Kamfanin. (NYSE: LLY) ya sanar a yau. Amfanin asibiti ya nuna ƙayyadaddun ƙayyadaddun ƙarshen ƙarshen abin da ya haɗa da duk sanadin mace-mace, yawan abubuwan da suka faru na gazawar zuciya, lokaci zuwa aukuwar raunin zuciya na farko da alamomi kamar yadda aka auna ta Kansas City Cardiomyopathy Questionnaire jimlar alamar alama (KCCQ-TSS). An buga sakamakon binciken a cikin Magungunan Halittu kuma an gabatar da su a Taron Kimiyya na Late-Breaking Scientific Association na Amurka 2021.            

"Watanni na farko da suka biyo bayan asibiti don rashin ciwon zuciya lokaci ne na musamman ga marasa lafiya," in ji Adriaan Voors, Farfesa na Cardiology, Jami'ar Medical Center, Groningen, Netherlands, da EMPULSE babban mai binciken. “Sakamakon da ake samu a halin yanzu ba su da kyau, yana mai nuna bukatar gaggawa na inganta kulawar marasa lafiya don hana ci gaba da asibiti ko mutuwa. Wannan fa'idar asibiti mai mahimmanci tare da empagliflozin idan aka kwatanta da placebo zai haɓaka fahimtarmu game da maganin cututtukan zuciya yayin lokacin fitarwa na farko.

Rashin ciwon zuciya shine babban dalilin asibiti, yana lissafin fiye da miliyan 1 a kowace shekara a Amurka Sakamakon wadanda aka kwantar da su a asibiti don ciwon zuciya ba su da kyau, tare da fiye da 30% na marasa lafiya da aka sake karbar su a cikin kwanaki 90 tsakanin 2010 da 2017. , bisa ga National Readmission Database.

Gabaɗayan fa'idar asibiti tare da Jardiance ya yi daidai ga waɗanda ke da sabon ko wanda ke da gazawar zuciya, ga waɗanda ke da ko marasa ciwon sukari da kuma waɗanda ke da ko dai kiyayewa ko rage juzu'in fitarwa. A cikin ƙarshen ƙarshen binciken na biyu, Jardiance ya inganta KCCQ-TSS sosai daga tushe zuwa rana ta 90 ta maki 4.5 tare da placebo.

Sakamakon aminci na EMPULSE ya yi daidai da ingantaccen ingantaccen bayanin martaba na Jardiance. Mai bincike ya ba da rahoton m ƙimar gazawar koda ya kasance 7.7% na Jardiance da 12.1% na placebo, kuma akwai irin wannan ƙarancin ƙarancin hypoglycemia a cikin ƙungiyoyin biyu (1.9% na Jardiance vs. 1.5% don placebo). Adadin raguwar ƙarar ya kasance 12.7% zuwa 10.2%, bi da bi.

"Muna samun ƙarfafa ta farkon da fa'idar asibiti ta farko da aka gani a cikin EMPULSE tare da Jardiance lokacin da aka fara a cikin manya waɗanda ke fama da gazawar zuciya tare da kiyayewa ko rage juzu'in fitarwa kafin a sallame asibiti, gami da haɓakawa a ƙarshen ƙarshen hada mace-mace, asibiti da ingancin rayuwa, " Mohamed Eid, MD, MPH, MHA, mataimakin shugaban kasa, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. taimaka wa mutanen da ke da nau'ikan yanayin cututtukan zuciya-renal-metabolism waɗanda ake buƙatar ƙarin zaɓuɓɓukan magani don su sosai."

"Sakamakon EMPULSE yana ƙara haɓakar nauyin shaida daga shirinmu na EMPOWER wanda ke goyan bayan yuwuwar rawar Jardiance a cikin yanayin yanayin da ke shafar zuciya, kodan da tsarin rayuwa," in ji Jeff Emmick, MD, Ph.D., mataimakin shugaban kasa, Haɓaka Samfur, Lilly. "Fa'idar asibiti da daidaitattun sakamakon aminci da aka nuna a cikin yanayin rashin ƙarfi bayan fitowar asibiti sun nuna cewa farawa a asibiti tare da Jardiance ga marasa lafiya masu dacewa na iya inganta sakamako a cikin waɗannan watanni masu mahimmanci."

Kwanan nan, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da Jardiance don rage haɗarin mutuwar cututtukan zuciya da kuma asibiti don raunin zuciya a cikin manya tare da gazawar zuciya dangane da bayanai daga gwajin EMPEROR-Preserved®. Wannan shawarar ita ce amincewar FDA ta uku ga Jardiance da ta fito daga shirin EMPOWER.

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...